Cti Biopharma (CTIC) Return on Equity ROE from the first quarter 2023 to first quarter 2022 and annually, average high and low, overall ranking from Mar 31 2023 to Mar 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cti Biopharma Corp   (NASDAQ: CTIC)

Cti Biopharma 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Cti Biopharma in the first quarter 2023?
Due to the lack of equity, it was not possible to calculate Cti Biopharma Corp 's return on equity (ROE) in its first quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -69 -93 -112 -121 -118
Return On Equity (TTM) - - - -5105.49 % -616.49 %
CTIC's Total Ranking # # # # #
Equity (TTM) in Millions -25 -18 -17 -5 -28
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to CTIC Management Effectiveness >> CTIC's 5 Years Annual ROE >> Compare CTIC ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





CTIC Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Equity in Millions -18 4 40 18 53
Y / Y Equity Change - -90.59 % 123.25 % -66.13 % 229.02 %
Net Income in Millions -93 -98 -52 -40 -29
Y / Y Net Income Change - - - - -
Return On Equity - -2599.1 % -131.03 % -223.22 % -55.44 %

Back to CTIC Management Effectiveness >> CTIC's 5 Years Annual ROE >> Compare CTIC ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CTIC's' Return on Equity at Yahoo Finance
CTIC's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CTIC's Competitors
Subscribers only: Roe for Cti Biopharma 's Suppliers
Subscribers only: Return On Equity for CTIC's Customers




Companies with similar Return On Equity at Mar 31 2023, within Healthcare Sector ROE
Inhibitor Therapeutics Inc   578.74 %
Theravance Biopharma inc   371.53 %
Omeros Corporation  303.40 %
Amgen Inc   209.99 %
Talphera Inc   178.53 %
Ir med Inc   177.83 %
Waters Corporation  168.10 %
Gyre Therapeutics Inc   130.10 %
Idexx Laboratories Inc  117.37 %
Halozyme Therapeutics Inc   116.10 %
Biomx Inc  109.90 %
Voyager Therapeutics Inc   95.18 %
Aptevo Therapeutics Inc   92.44 %
Davita Inc   88.54 %
Chimerix Inc   87.89 %

Date modified: 2026-09-08T15:10:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.